Clinical Benefits of Denosumab vs Zoledronate in Postmenopausal Women Previously Treated with Alendronate: A Two-Year Retrospective Study. [PDF]
Wang Z +7 more
europepmc +1 more source
Updated Advances on Drugs and Bone-Targeting Nanoparticles for Osteoporosis Therapy: Carrier Materials, Modification, Function Mechanism, and Applications-A Systematic Review. [PDF]
Lin Y +6 more
europepmc +1 more source
Isolated Atypical Pedicle Stress Fractures in Patients on Prolonged Bisphosphonate Therapy: Report of Two Cases and a Literature-Based Proposal for Diagnostic Criteria. [PDF]
Auron M +3 more
europepmc +1 more source
Treatment-related changes in total hip bone mineral density are applicable to trials of varied study designs and to drugs with differing mechanisms of action: meta-regression results from the FNIH-ASBMR SABRE study. [PDF]
Vilaca T +9 more
europepmc +1 more source
Alendronate sodium demonstrates significant clinical advantages in treating osteoporosis secondary to severe fractures. [PDF]
Wang S, Ye L, Hang Q.
europepmc +1 more source
Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate. [PDF]
Mei Y +8 more
europepmc +1 more source
Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide. [PDF]
Cosman F +6 more
europepmc +1 more source
Bisphosphonates with high bone-resorption-capacity promote osteonecrosis of the jaw development after tooth extraction in mice. [PDF]
Kubo R +4 more
europepmc +1 more source
Treatment of osteoporosis in the solid organ transplant recipient: an organ-based approach. [PDF]
Kurnool S, Shah N, Ekanayake P.
europepmc +1 more source

